• Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues


Zoetis Inc Expands Kalamazoo, Michigan, Manufacturing & Distribution Hub

Zoetis Inc., a leading animal health company, plans to expand capacity at its Global Manufacturing and Supply facility in Kalamazoo, Michigan.

Renovations to the 524,000-square foot facility in Kalamazoo will expand production of Simparica (sarolaner) Chewables, the innovative oral flea and tick medication for dogs, which was approved by the U.S. Food and Drug Administration in February 2016. The company expects to begin renovations later this month and to complete the project by early 2019.

Zoetis will install two new production lines and related operations to manufacture oral tablet and chewable medicines for companion animals. The company expects to add up to 45 manufacturing positions in the next three years. The company currently employs approximately 300 colleagues at its manufacturing facilities in Kalamazoo and Portage, including 265 dedicated directly to manufacturing.

“Kalamazoo is home to one of the largest and most important manufacturing sites in Zoetis’ Global Manufacturing and Supply network,” said Matthew Everhart, Vice President, Pharmaceutical and Aseptic Operations, Global Manufacturing and Supply at Zoetis.

“Locating manufacturing here gives us continued access to a highly skilled and diverse workforce which is essential to managing a global animal health company. Our people provide our veterinarian and livestock farmer customers with a reliable supply of high quality medicines for their animals and are an integral part of the community here,” he added.

“We are committed to enhancing our manufacturing operations in Kalamazoo and thank the Michigan Economic Development Corporation, the cities of Kalamazoo and Portage, and Southwest Michigan First for their efforts to attract and help businesses grow in Michigan.”

The Michigan Economic Development Corporation (MEDC) awarded Zoetis a Business Development Program incentive grant.

“Today’s investment announcement by Zoetis will foster a long-term positive impact on western Michigan’s economy and bring new jobs to the area. Numerous public and private partners deserve thanks for helping make this project happen, and we are pleased to support that collaboration,” said MEDC Chief Executive Officer Steve Arwood. “Zoetis’ decision to bolster its production of medicines here demonstrates that our business climate and our state’s world-class talent make Michigan a top destination for biotech companies to locate, expand and grow new jobs.”

Exclusive Research